FIELD: chemistry; pharmaceutics.
SUBSTANCE: group of inventions relates to chemistry and pharmaceutics, specifically to a solid pharmaceutical composition for treating atopic dermatitis; to embodiments of its production method; as well as to embodiments of a method of treating atopic dermatitis, which involve administering to an animal in need thereof an effective amount of said solid pharmaceutical composition. Disclosed composition is a tablet and contains: a) a pharmaceutically effective amount of a compound of formula (I) 
, dispersed in a polymer matrix, which is hydroxypropyl methylcellulose acetate succinate (HPMCAS), where the weight ratio of the polymer to the compound of formula (I) is from 10:1 to 5:1, wherein the compound of formula (I) is present in amorphous form; and b) a pharmaceutically acceptable carrier.
EFFECT: group of inventions provides higher bioavailability of the compound of formula (I).
29 cl, 3 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION OF THE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | 2014 |
|
RU2661399C1 |
| CRTH2 ANTAGONIST PARTICLES | 2008 |
|
RU2468012C2 |
| SOLID DISPERSIONS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SUBSTITUTED INDANE, AND METHODS FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2772693C1 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBRIOSIS | 2019 |
|
RU2822220C2 |
| PHARMACEUTICAL COMPOSITION AND ITS ADMINISTERING | 2013 |
|
RU2802442C2 |
| PHARMACEUTICAL COMPOSITION AND INTRODUCTION THEREOF | 2013 |
|
RU2692779C2 |
| AMINE SALTS OF CRTH2 ANTAGONIST | 2008 |
|
RU2468013C2 |
| COMPOSITIONS OF SOLID DOSAGE FORMS OF OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2759837C2 |
| COMPOSITIONS OF SOLID DOSAGE FORMS OF AN OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2699358C2 |
| SOLID FORMS OF (R)-1-(2,2-DIFLUOROBENZO[d][1,3]DIOXOL-5-YL)-N-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANE CARBOXAMIDE | 2011 |
|
RU2573830C2 |
